Emerging hormonal treatments for menopausal symptoms

Bibliography

• Avis NE, Crawford SL, McKinlay SM. Psychosocial, behavioral, and health factors related to menopause symptomatology. Womens Health 1997;3:103-20
   PubMedGoogle Scholar
• Williams RE, Kalilani L, DiBenedetti DB, et al. Frequency and severity of vasomotor symptoms among peri- and postmenopausal women in the United States. Climacteric 2008;11:32-43
   PubMed Web of Science ®Google Scholar
• Politi MC, Schleinitz MD, Col NF. Revisiting the duration of vasomotor symptoms of menopause: a meta-analysis. J Gen Intern Med 2008;23:1507-13
   PubMed Web of Science ®Google Scholar
• Barnabei VM, Cochrane BB, Aragaki AK, et al. Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women’s Health Initiative. Obstet Gynecol 2005;105:1063-73
   PubMed Web of Science ®Google Scholar
• Mac Bride MB, Rhodes DJ, Shuster LT. Vulvovaginal atrophy. Mayo Clin Proc 2010;85:87-94
   PubMed Web of Science ®Google Scholar
• The North American Menopause Society. Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010;17:25-54
   PubMed Web of Science ®Google Scholar
• Hemminki E, Regushevskaya E, Luoto R, Veerus P. Variability of bothersome menopausal symptoms over time–a longitudinal analysis using the Estonian postmenopausal hormone therapy trial (EPHT). BMC Womens Health 2012;12:44
   PubMedGoogle Scholar
• Utian WH. Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review. Health Qual Life Outcomes 2005;3:47
   PubMedGoogle Scholar
• Simon JA, Nappi RE, Kingsberg SA, et al. Clarifying Vaginal Atrophy’s Impact on Sex and Relationships (CLOSER) survey: emotional and physical impact of vaginal discomfort on North American postmenopausal women and their partners. Menopause 2014;21:137-42
   PubMed Web of Science ®Google Scholar
• Riggs BL, Hartmann LC. Selective estrogen-receptor modulators – mechanisms of action and application to clinical practice. N Engl J Med 2003;348:618-29
   PubMed Web of Science ®Google Scholar
• The North American Menopause Society. The 2012 hormone therapy position statement of: the North American Menopause Society. Menopause 2012;19:257-71
   PubMed Web of Science ®Google Scholar
• Ameye L, Antoine C, Paesmans M, et al. Menopausal hormone therapy use in 17 European countries during the last decade. Maturitas 2014. [ Epub ahead of print]
   Web of Science ®Google Scholar
• Sprague BL, Trentham-Dietz A, Cronin KA. A sustained decline in postmenopausal hormone use: results from the National Health and Nutrition Examination Survey, 1999-2010. Obstet Gynecol 2012;120:595-603
   PubMed Web of Science ®Google Scholar
• Komm BS. A new approach to menopausal therapy: the tissue selective estrogen complex. Reprod Sci 2008;15:984-92
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women’s Health Initiative Randomized Trial. JAMA 2003;289:3243-53
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Anderson GL, Gass M, et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 2010;304:1684-92
   PubMed Web of Science ®Google Scholar
• Anderson GL, Chlebowski RT, Aragaki AK, et al. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women’s Health Initiative randomised placebo-controlled trial. Lancet Oncol 2012;13:476-86
   PubMed Web of Science ®Google Scholar
• Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the women’s health initiative randomized trials. JAMA 2013;310:1353-68
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Guidance for Industry Noncontraceptive Estrogen Drug Products for the Treatment of Vasomotor Symptoms and Vulvar and Vaginal Atrophy Symptoms - Recommended Prescribing Information for Health Care Providers and Patients Labeling. Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM135336.pdf [Last accessed 13 October 2014]
   Google Scholar
• Food and Drug Administration. Estrogen and estrogen with progestin therapies for postmenopausal women. Available from: http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm135318.htm [Last accessed 13 October 2014]
   Google Scholar
• Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465-77
   PubMed Web of Science ®Google Scholar
• Love RR, Mazess RB, Barden HS, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992;326:852-6
   PubMed Web of Science ®Google Scholar
• Jordan VC, Morrow M. Tamoxifen, raloxifene, and the prevention of breast cancer. Endocr Rev 1999;20:253-78
   PubMed Web of Science ®Google Scholar
• Cauley JA, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 2001;65:125-34
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006;355:125-37
   PubMed Web of Science ®Google Scholar
• Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88
   PubMed Web of Science ®Google Scholar
• Christiansen C, Chesnut CHIII, Adachi JD, et al. Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled Phase 3 study of postmenopausal women with osteoporosis. BMC Musculoskelet Disord 2010;11:130
   PubMed Web of Science ®Google Scholar
• Silverman SL, Christiansen C, Genant HK, et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 2008;23:1923-34
   PubMed Web of Science ®Google Scholar
• Ronkin S, Northington R, Baracat E, et al. Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women. Obstet Gynecol 2005;105:1397-404
   PubMed Web of Science ®Google Scholar
• Miller PD, Chines AA, Christiansen C, et al. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res 2008;23:525-35
   PubMed Web of Science ®Google Scholar
• Brisdelle [package insert]. Noven Therapeutics, LLC; Miami, FL: 2013
   Google Scholar
• Simon JA, Portman DJ, Kaunitz AM, et al. Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms: two randomized controlled trials. Menopause 2013;20:1027-35
   PubMed Web of Science ®Google Scholar
• Portman DJ, Kaunitz AM, Kazempour K, et al. Effects of low-dose paroxetine 7.5 mg on weight and sexual function during treatment of vasomotor symptoms associated with menopause. Menopause 2014;21:1082-90
   PubMed Web of Science ®Google Scholar
• Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 2004;291:1701-12
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321-33
   PubMed Web of Science ®Google Scholar
• Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-27
   PubMed Web of Science ®Google Scholar
• North American Menopause Society. HT prescriptions: a continued slow decline in 2010 (except for vaginal estrogens). Available from: http://www.menopause.org/publications/clinical-practice-materials/Htstatistics [Last accessed 9 May 2014]
   Google Scholar
• Power ML, Anderson BL, Schulkin J. Attitudes of obstetrician-gynecologists toward the evidence from the Women’s Health Initiative hormone therapy trials remain generally skeptical. Menopause 2009;16:500-8
   PubMed Web of Science ®Google Scholar
• American College of Obstetricians and Gynecologists. Committee opinion no. 532: compounded bioidentical menopausal hormone therapy. Available from: http://www.acog.org/Resources-And-Publications/Committee-Opinions/Committee-on-Gynecologic-Practice/Compounded-Bioidentical-Menopausal-Hormone-Therapy [Last accessed 21 August 2014]
   Google Scholar
• Pickar JH, MacNeil T, Ohleth K. SERMs: progress and future perspectives. Maturitas 2010;67:129-38
   PubMed Web of Science ®Google Scholar
• Chang KC, Wang Y, Bodine PV, et al. Gene expression profiling studies of three SERMs and their conjugated estrogen combinations in human breast cancer cells: insights into the unique antagonistic effects of bazedoxifene on conjugated estrogens. J Steroid Biochem Mol Biol 2010;118:117-24
   PubMed Web of Science ®Google Scholar
• Ethun KF, Wood CE, Register TC, et al. Effects of bazedoxifene acetate with and without conjugated equine estrogens on the breast of postmenopausal monkeys. Menopause 2012;19:1242-52
   PubMed Web of Science ®Google Scholar
• Ethun KF, Wood CE, Cline JM, et al. Endometrial profile of bazedoxifene acetate alone and in combination with conjugated equine estrogens in a primate model. Menopause 2013;20:777-84
   PubMed Web of Science ®Google Scholar
• Axlund SD, Sartorius CA. Progesterone regulation of stem and progenitor cells in normal and malignant breast. Mol Cell Endocrinol 2012;357:71-9
   PubMed Web of Science ®Google Scholar
• Liang Y, Benakanakere I, Besch-Williford C, et al. Synthetic progestins induce growth and metastasis of BT-474 human breast cancer xenografts in nude mice. Menopause 2010;17:1040-7
   PubMed Web of Science ®Google Scholar
• Brisken C. Progesterone signalling in breast cancer: a neglected hormone coming into the limelight. Nat Rev Cancer 2013;13:385-96
   PubMed Web of Science ®Google Scholar
• Rivas MA, Venturutti L, Huang YW, et al. Downregulation of the tumor-suppressor miR-16 via progestin-mediated oncogenic signaling contributes to breast cancer development. Breast Cancer Res 2012;14:R77
   PubMedGoogle Scholar
• Tkach M, Rosemblit C, Rivas MA, et al. p42/p44 MAPK-mediated Stat3Ser727 phosphorylation is required for progestin-induced full activation of Stat3 and breast cancer growth. Endocr Relat Cancer 2013;20:197-212
   PubMed Web of Science ®Google Scholar
• Osphena [package insert]. Shionogi, Inc; Florham Park, NJ: 2013
   Google Scholar
• European Medicines Agency. Applications for new human medicines under evaluation by the committee for medicinal products for human use. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Report/2014/07/WC500169655.pdf [Last accessed 10 July 2014]
   Google Scholar
• Duavee [package insert]. Wyeth Pharmaceuticals, Inc., A subsidiary of Pfizer, Inc; Philadelphia, PA: 2013
   Google Scholar
• Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2006(4):CD001500
   Google Scholar
• The North American Menopause Society. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause 2013;20:888-902
   PubMed Web of Science ®Google Scholar
• TherapeuticsMD. NYSE MKT: TXMD Corporate Overview. Available from: http://www.therapeuticsmd.com/presentations.aspx [Last accessed 13 May 2014]
   Google Scholar
• ClinicalTrials.gov. Safety & efficacy WC3011 in the treatment of vulvovaginal atrophy in postmenopausal women (VENUS) NCT01400776. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01400776?term=vulvovaginal+atrophy&rank=1 [Last accessed 9 May 2014]
   Google Scholar
• ClinicalTrials.gov. Evaluate long-term safety and efficacy WC3011 NCT01455597. Available from: http://www.clinicaltrials.gov/ct2/show/study/NCT01455597?term=vulvovaginal+atrophy&rank=2 [Last accessed 9 May 2014]
   Google Scholar
• ClinicalTrials.gov. Study to evaluate safety & efficacy of WC3011 in postmenopausal women with dyspareunia. NCT01845649. Available from: http://www.clinicaltrials.gov/ct2/show/study/NCT01845649?term=vulvovaginal+atrophy&rank=8 [Last accessed 9 May 2014]
   Google Scholar
• ClinicalTrials.globe24g.com. Evaluate long-term safety and efficacy WC3011. NCT01455597 Available from: http://clinicaltrials.globe24h.com/0/0/symptoms-and-general-pathology/a/atrophy/2011/10/17/nct01455597-evaluate-long-term-safety-and-efficacy-wc3011-warner-chilcott.shtml [Last accessed 9 May 2014]
   Google Scholar
• ClinicalTrials.gov. Multicenter study to evaluate safety and efficacy of WC3011 in postmenopausal women. NCT01816139 Available from: http://clinicaltrials.gov/ct2/show/NCT01816139 [Last accessed 9 May 2014]
   Google Scholar
• Business Wire. TherapeuticsMD reports positive results of rabbit irritation study for its estradiol vaginal capsule VagiCap™ (TX 004-HR) for treatment of vulvar vaginal atrophy (VVA) [press release]. Available from: http://www.businesswire.com/news/home/20140407005470/en/TherapeuticsMD-Reports-Positive-Results-Rabbit-Irritation-Study#.U3OtSPldX9Z [Last accessed 13 May 2014]
   Google Scholar
• TherapeuticsMD. TherapeuticsMD reports positive PK study results for its estradiol vaginal capsule VagiCap™ (TX 12-004-HR) for treatment of vulvar vaginal atrophy (VVA) [press release]. Available from: http://www.therapeuticsmd.com/pressreleases.aspx [Last accessed 13 May 2014]
   Google Scholar
• PBR Contract Research & Services Clinical Trial. TherapeuticsMD reports positive PK study results for vulvar vaginal atrophy drug [press release]. Available from: http://clinicaltrials.pharmaceutical-business-review.com/news/therapeuticsmd-reports-positive-pk-study-results-for-vulvar-vaginal-atrophy-drug-290114-4167592 [Last accessed 9 May 2014]
   Google Scholar
• Food and Drug Administration. Compounded menopausal hormone therapy questions and answers. Available from: http://www.fda.gov/drugs/guidancecomplianceregulatoryinformation/pharmacycompounding/ucm183088.htm [Last accessed 14 May 2014]
   Google Scholar
• American College of Obstetricians and Gynecologists. Practice bulletin no. 141: management of menopausal symptoms. Obstet Gynecol 2014;123:202-16
   PubMed Web of Science ®Google Scholar
• Business Wire. TherapeuticsMD to present the design of its REPLENISH trial at the International Menopause Society’s 14th World Congress [press release]. Available from: http://www.businesswire.com/news/home/20140501006446/en/TherapeuticsMD-Present-Design-REPLENISH-Trial-International-Menopause#.U3OxOPldX9Z [Last accessed 12 May 2014]
   Google Scholar
• Pickar JH, Bon C, Amadio JM, Bernick B. Pharmacokinetics of the first combination 15ß-estradiol/progesterone capsule in clinical development for hormone therapy [abstract P-81]. Presented at: annual Meeting of the North American Menopause Society; 9 – 12 October 2013; Grapevine, TX
   Google Scholar
• ClinicalTrials.gov. A safety and efficacy study of the combination estradiol and progesterone to treat vasomotor symptoms (REPLENISH) NCT01942668. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01942668?term=REPLENISH&rank=1 [Last accessed 21 April 2014]
   Google Scholar
• ClinicalTrials.gov. Dehydroepiandrosterone (DHEA) + acolbifene against vasomotor symptoms (hot flushes) in postmenopausal women. NCT01452373. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01452373?term=acolbifene&rank=1 [Last accessed 9 May 2014]
   Google Scholar
• Femivia™. Endoceutics. Available from: http://www.endoceutics.com/our-products/femivia8482/?no_cache=1&sword_list[0]=femivia [Last accessed 12 May 2014]
   Google Scholar
• Labrie F. DHEA, important source of sex steroids in men and even more in women. Prog Brain Res 2010;182:97-148
   PubMed Web of Science ®Google Scholar
• Goss PE, Qi S, Cheung AM, et al. The selective estrogen receptor modulator SCH 57068 prevents bone loss, reduces serum cholesterol and blocks estrogen-induced uterine hypertrophy in ovariectomized rats. J Steroid Biochem Mol Biol 2004;92:79-87
   PubMed Web of Science ®Google Scholar
• Berger L, El-Alfy M, Martel C, Labrie F. Effects of dehydroepiandrosterone, Premarin and Acolbifene on histomorphology and sex steroid receptors in the rat vagina. J Steroid Biochem Mol Biol 2005;96:201-15
   PubMed Web of Science ®Google Scholar
• Pelletier G, Ouellet J, Martel C, Labrie F. Androgenic action of dehydroepiandrosterone (DHEA) on nerve density in the ovariectomized rat vagina. J Sex Med 2013;10:1908-14
   PubMed Web of Science ®Google Scholar
• Bachmann GA, Komi JO. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. Menopause 2010;17:480-6
   PubMed Web of Science ®Google Scholar
• Portman DJ, Bachmann GA, Simon JA. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. Menopause 2013;20:623-30
   PubMed Web of Science ®Google Scholar
• Goldstein SR, Bachmann GA, Koninckx PR, et al. Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy. Climacteric 2014;17:173-82
   PubMed Web of Science ®Google Scholar
• Simon JA, Lin VH, Radovich C, Bachmann GA. One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus. Menopause 2013;20:418-27
   PubMed Web of Science ®Google Scholar
• Kharode Y, Bodine PV, Miller CP, et al. The pairing of a selective estrogen receptor modulator, bazedoxifene, with conjugated estrogens as a new paradigm for the treatment of menopausal symptoms and osteoporosis prevention. Endocrinology 2008;149:6084-91
   PubMed Web of Science ®Google Scholar
• Liu S, Han SJ, Smith CL. Cooperative activation of gene expression by agonists and antagonists mediated by estrogen receptor heteroligand dimer complexes. Mol Pharmacol 2013;83:1066-77
   PubMed Web of Science ®Google Scholar
• Lewis-Wambi JS, Kim H, Curpan R, et al. The selective estrogen receptor modulator bazedoxifene inhibits hormone-independent breast cancer cell growth and down-regulates estrogen receptor alpha and cyclin D1. Mol Pharmacol 2011;80:610-20
   PubMed Web of Science ®Google Scholar
• Wardell SE, Nelson ER, Chao CA, McDonnell DP. Bazedoxifene exhibits antiestrogenic activity in animal models of tamoxifen-resistant breast cancer: implications for treatment of advanced disease. Clin Cancer Res 2013;19:2420-31
   PubMed Web of Science ®Google Scholar
• Pickar JH, Yeh IT, Bachmann G, Speroff L. Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy. Fertil Steril 2009;92:1018-24
   PubMed Web of Science ®Google Scholar
• Lobo RA, Pinkerton JV, Gass ML, et al. Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. Fertil Steril 2009;92:1025-38
   PubMed Web of Science ®Google Scholar
• Archer DF, Lewis V, Carr BR, et al. Bazedoxifene/conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women. Fertil Steril 2009;92:1039-44
   PubMed Web of Science ®Google Scholar
• Lindsay R, Gallagher JC, Kagan R, et al. Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women. Fertil Steril 2009;92:1045-52
   PubMed Web of Science ®Google Scholar
• Harvey JA, Pinkerton JV, Baracat EC, et al. Breast density changes in a randomized controlled trial evaluating bazedoxifene/conjugated estrogens. Menopause 2013;20:138-45
   PubMed Web of Science ®Google Scholar
• Pinkerton JV, Utian WH, Constantine GD, et al. Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial. Menopause 2009;16:1116-24
   PubMed Web of Science ®Google Scholar
• Utian W, Yu H, Bobula J, et al. Bazedoxifene/conjugated estrogens and quality of life in postmenopausal women. Maturitas 2009;63:329-35
   PubMed Web of Science ®Google Scholar
• Kagan R, Williams RS, Pan K, et al. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women. Menopause 2010;17:281-9
   PubMed Web of Science ®Google Scholar
• Bachmann G, Bobula J, Mirkin S. Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy. Climacteric 2010;13:132-40
   PubMed Web of Science ®Google Scholar
• Mirkin S, Komm BS, Pan K, Chines AA. Effects of bazedoxifene/conjugated estrogens on endometrial safety and bone in postmenopausal women. Climacteric 2013;16:338-46
   PubMed Web of Science ®Google Scholar
• Pinkerton JV, Harvey JA, Pan K, et al. Breast effects of bazedoxifene-conjugated estrogens: a randomized controlled trial. Obstet Gynecol 2013;121:959-68
   PubMed Web of Science ®Google Scholar
• Pinkerton JV, Pan K, Abraham L, et al. Sleep parameters and health-related quality of life with bazedoxifene/conjugated estrogens: a randomized trial. Menopause 2014;21:252-9
   PubMed Web of Science ®Google Scholar
• Pinkerton JV, Harvey JA, Lindsay R, et al. Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial. J Clin Endocrinol Metab 2014;99:E189-98
   PubMed Web of Science ®Google Scholar
• LaCroix AZ, Powles T, Osborne CK, et al. Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. J Natl Cancer Inst 2010;102:1706-15
   PubMed Web of Science ®Google Scholar
• McClung MR, Siris E, Cummings S, et al. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene. Menopause 2006;13:377-86
   PubMed Web of Science ®Google Scholar
• Stovall DW, Utian WH, Gass ML, et al. The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety. Menopause 2007;14:510-17
   PubMed Web of Science ®Google Scholar
• Carranza-Lira S, Gooch AL, Saldivar N, Osterwalder MS. Climacteric symptom control after the addition of low-dose esterified conjugated estrogens to raloxifene standard doses. Int J Fertil Womens Med 2007;52:93-6
   PubMedGoogle Scholar
• Peano BJ, Crabtree JS, Komm BS, et al. Effects of various selective estrogen receptor modulators with or without conjugated estrogens on mouse mammary gland. Endocrinology 2009;150:1897-903
   PubMed Web of Science ®Google Scholar
• Pluchino N, Drakopoulos P, Bianchi-Demicheli F, et al. Neurobiology of DHEA and effects on sexuality, mood and cognition. J Steroid Biochem Mol Biol 2014. [ Epub ahead of print]
   Web of Science ®Google Scholar
• Genazzani AR, Stomati M, Valentino V, et al. Effect of 1-year, low-dose DHEA therapy on climacteric symptoms and female sexuality. Climacteric 2011;14:661-8
   PubMed Web of Science ®Google Scholar
• Huang P, Chandra V, Rastinejad F. Structural overview of the nuclear receptor superfamily: insights into physiology and therapeutics. Annu Rev Physiol 2010;72:247-72
   PubMed Web of Science ®Google Scholar
• Berrodin TJ, Chang KC, Komm BS, et al. Differential biochemical and cellular actions of Premarin estrogens: distinct pharmacology of bazedoxifene-conjugated estrogens combination. Mol Endocrinol 2009;23:74-85
   PubMed Web of Science ®Google Scholar
• Kulak JJr, Fischer C, Komm B, Taylor HS. Treatment with bazedoxifene, a selective estrogen receptor modulator, causes regression of endometriosis in a mouse model. Endocrinology 2011;152:3226-32
   PubMed Web of Science ®Google Scholar